Other drug agents
MedKoo product information:
Description of CEP-11981:
Description of CEP-11981:CEP-11981 is an orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR) and Tie2 receptor tyrosine kinases with potential antiangiogenic and antineoplastic activities. Pan-VEGFR/Tie2 tyrosine kinase inhibitor CEP-11981 selectively binds to VEGFR and Tie2 receptor tyrosine kinases, which may result the inhibition of endothelial cell migration, proliferation and survival and the inhibition of tumor cell proliferation and tumor cell death. VEGFR and Tie2 are frequently overexpressed by a variety of tumor cell types and play crucial roles in the regulation of angiogenesis and the maintenance of tumor blood vessels. Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains) is activated by angiopoietin-1 (Ang-1). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
Current developer: Cephalon, Inc
1: Hudkins RL, Becknell NC, Zulli AL, Underiner TL,
Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K,
Jones-Bolin S, Zhao H, Bacon ER, Mallamo JP, Ator MA, Ruggeri BA.
Synthesis and biological profile of the pan-vascular endothelial growth
factor receptor/tyrosine kinase with immunoglobulin and epidermal growth
factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor
(Keyword; CAS#; MedKoo code#)
About us | Services | Products | News | Careers | Contact us